Who owns Prime Medicine, Inc. (PRME)? Elite investor 13F holders
3 tracked elite investors reported holding Prime Medicine, Inc as of 2026-06-30, including Alphabet, D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alphabet | PRIME MEDICINE INC | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 61115618.00 USD | 16562498.000000 | Shares | hold | Original filing |
| D.E. Shaw | PRIME MEDICINE INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2394589.00 USD | 648940.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | PRIME MEDICINE INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 433250.00 USD | 117412.000000 | Shares | reduce | Original filing |
| Tudor Investment | PRIME MEDICINE INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.